As we reported here, on September 16, 2025, FDA published over 55 warning letters to online sellers of compounded versions of GLP-1, the popular weight-loss injections marketed as Wegovy (semaglutide injection, manufactured by Novo Nordisk) and Zepbound (tirzepatide injection, manufactured by Eli Lilly)
It is a week you can still understand when the routine feels messy
This can put them at risk for dehydration if they dont drink enough water
Read the full press release here: Download our Trend Report Navigating Weight Loss Medications in 2025 and learn where the industry is headed next
Maintaining adequate dietary fat intake during treatment and not losing weight too rapidly may help reduce this risk
Luzzatti notes that while standard PAs typically require a trial-and-failure history with a first-line therapy like metformin, the enforcement is often easily circumvented